Clinical Observation of Buyang Huanwu Decoction Combined with Butylphthalein in the Treatment of Chronic Cerebral Ischemia Patients with Qi Deficiency and Blood Stasis
Objective:To study the clinical observation of Buyang Huanwu Decoction combined with butylphtha-lein in the treatment of chronic cerebral ischemia(CCI)with Qi deficiency and blood stasis.Methods:From August 2021 to August 2022,60 CCI patients with qi-deficiency and blood-stasis who met the inclusion criteria were select-ed and randomly divided into a control group and a treatment group,30 cases each group.The control group was rou-tinely treated with butylphthalein and the treatment group was treated with Buyang Huanwu Decoction combined with butylphthalein for 2 months.For all the patients before and after treatment,TCM syndrome efficacy standard and score scale,Vertigo Disorder Rating Scale(DHI),Montreal Cognitive Assessment Scale(MoCA),Simple Mental State Scale(MMSE),cranial magnetic resonance perfusion-weighted imaging(PWI)data scores were used to monitor.Results:The total clinical effective rate of the control group was 73.33％and that of the treatment group was 86.67％,and the total effective rate of the treatment group was significantly higher than that of the control group(P＜0.05),and the scores of TCM symptom score,DHI,MoCA,MMSE and PWI data of the control group were significantly higher than that of the treatment group(P＜0.05).Conclusion:Butylphthalein can effectively treat chronic cerebral ischemia patients with qi deficiency and blood stasis,but Buyang Huanwu Decoction combined with butylphthalein has more significant effect in treating chronic cerebral ischemia with qi deficiency and blood stasis type(P＜0.05).
Buyang Huanwu DecoctionButylphthaleinChronic Cerebral Ischemia with Qi Deficiency and Blood StasisCerebral Magnetic Resonance Perfusion-Weighted Imaging
NETL
NSTL
万方数据
